Analysis of risk factors and outcome of Intravitreal anti-VEGF in retinal vein occlusion
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Role of biochemical markers in patients newly diagnosed with Retinal Vein Occlusion (RVO)
研究概览
简要总结
This prospective observational study aims to analyze the role of biochemical abnormalities—Vitamin B12 deficiency, hyperhomocysteinemia, and Protein C/S deficiencies—in the development and prognosis of Retinal Vein Occlusion (RVO). Forty newly diagnosed RVO patients with macular edema will undergo biochemical testing, ocular examination, and OCT imaging, followed by intravitreal anti-VEGF treatment. Visual acuity and macular thickness will be monitored over a period of 3 months. The study seeks to determine whether these biochemical abnormalities increase RVO risk and influence response to anti-VEGF therapy.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 80.00 Year(s)（—）
- 性别
- All
入选标准
- •Treatment naive cases of RVO Presence of clinically significant macular oedema secondary to RVO confirmed by OCT BCVA of 6 by 12 to 6 by 60 in the study eye CMT or CFT above 300 micrometer.
排除标准
- •Previous treatment for RVO in the study eye Retinal diseases other than RVO Significant media opacities Recent history of thromboembolic events.
结局指标
主要结局
Role of biochemical markers in patients newly diagnosed with Retinal Vein Occlusion (RVO)
时间窗: Baseline first visit, Post injection 1week, 1month, 3months
次要结局
- Therapeutic response in relation to pre-treatment biomarker influence(Baseline first visit, Post injection 1week,1month, 3months)
研究者
SUTHIKSHA V
Sankara Eye Hospital Coimbatore